SCHEMBL91046

SCHEMBL91046

BCC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17348242 1.00
SCHEMBL8273624 0.84
SCHEMBL10187340 0.84
SCHEMBL19058221 0.83
SCHEMBL12296164 0.83 ESR1 (0.38)
SCHEMBL19143895 0.83
SCHEMBL24270373 0.81
SCHEMBL12068011 0.81
SCHEMBL18799154 0.75
SCHEMBL16976231 0.72 PLG (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220127266-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-04-28 US disclosed
EP-2906539-B1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES HIVIH (FR) 2017-06-21 EP disclosed
WO-2013064543-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2013-05-10 WO disclosed
EP-2342191-B1 AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE MITSUBISHI TANABE PHARMA CORP (JP) 2013-03-20 EP disclosed
WO-2012168226-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2012-12-13 WO disclosed
US-20120114943-A1 CROSSLINKING SYSTEMS FOR HYDROXYL POLYMERS HEINZMAN STEPHEN WAYNE (US) 2012-05-10 US disclosed
US-8129449-B2 Crosslinking systems for hydroxyl polymers THE PROCTER & GABMLE COMPANY (US) 2012-03-06 US disclosed
US-8088843-B2 Crosslinking systems for hydroxyl polymers THE PROCTER & GAMBLE COMPANY (US) 2012-01-03 US disclosed
US-20110263113-A1 METHOD FOR MANUFACTURING A SEMICONDUCTOR DEVICE RENESAS ELECTRONICS CORPORATION (JP) 2011-10-27 US disclosed
EP-1237891-B1 HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2011-09-28 EP disclosed
EP-1389110-B1 INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME AVANIR PHARMACEUTICALS (US) 2010-03-24 EP disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed
EP-1011545-B1 RESORBABLE INTERBODY SPINAL FUSION DEVICES DEPUY MITEK INC (US) 2009-12-23 EP disclosed
US-20090095997-A1 EPITAXIAL SILICON GROWTH MICRON TECHNOLOGY, INC. (US) 2009-04-16 US disclosed
WO-2008060476-A2 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-05-22 WO disclosed
WO-2008046573-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS Grünenthal GmbH (DE) 2008-04-24 WO disclosed
EP-1463716-B1 PYRROLIDINE AND PIPERIDINE DERIVATES AS NK1 ANTAGONISTS SCHERING CORP (US) 2008-02-13 EP disclosed
EP-1326856-B1 PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY BAYER HEALTHCARE AG (DE) 2007-12-19 EP disclosed
WO-2007056469-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed
WO-2005121130-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2005-12-22 WO disclosed